Division of Becton Dickinson & Co.
Latest From Medivance Inc.
For therapeutic hypothermia device companies, the clinical trials that came before have been inconclusive, but they have provided insights to incorporate into the development of next-generation technologies. START-UP interviews two hypothermia device companies with novel approaches: Thermocure and ThermopeutiX.
Therapeutic hypothermia has shown promise as a neuroprotective treatment for a variety of applications, including cardiac arrest and neonatal hypoxic brain injury. Now companies with temperature management technologies are conducting clinical trials and developing new cooling devices with an eye toward cooling the brain in patients who experience an acute ischemic stroke – an indication with an estimated worldwide market potential of $3 billion annually.
Amir Belson is among the most prolific device entrepreneurs in the industry today, having launched a dozen companies in the past 12 years. Not as well-known as other physician-inventors, he combines an aggressive IP strategy with an innovative approach to early-stage financing to launch companies in a variety of clinical spaces.
Boston Scientific’s recent acquisition of Bard Electrophysiology marks the tenth notable acquisition that it has made since 2010. Four of those deals come in cardiac rhythm management, including EP, which is among the fastest-growing device sectors and one that company executives see as a major contributor to future growth.
- Monitoring Equipment & Devices
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Becton Dickinson & Co.
- Senior Management
Robert A Kline, Pres. & CEO
Robert M Holburn, Jr., VP, CFO
Steve Okland, VP, Sales & Mktg.
- Contact Info
Phone: (303) 926-5170
321 S. Taylor Ave.
Louisville, CO 80027
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.